Baird analyst Michael Ha lowered the firm’s price target on Elevance Health (ELV) to $297 from $492 and keeps a Neutral rating on the shares as part of an update on the managed care and healthcare facilities group. The firm is increasingly cautious on Medicaid and the healthcare exchange.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health’s (ELV) Earnings Blunder Entices Bullish Stock Option Traders
- Insiders Are Betting Big on These 2 Stocks – Should You Follow Their Lead?
- Elevance Health price target lowered to $327 from $358 at Barclays
- Target downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Argus downgrades Elevance Health to Hold on ongoing profit pressures